SCHEMBL21296909

SCHEMBL21296909

O=C(O)c1nn[nH]c1Oc1ccc(-c2ccc3ccccc3c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.48
ACMSD Q8TDX5 1/20 0.43
ALPL P05186 1/20 0.41
MCL1 Q07820 4/20 0.40
CTRC Q99895 1/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
MIF P14174 1/20 0.39
PRKAG1 P54619 1/20 0.39
PRKAA1 Q13131 1/20 0.39
PRKAB1 Q9Y478 1/20 0.39
HAO1 Q9UJM8 1/20 0.39
FTO Q9C0B1 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
EGLN3 Q9H6Z9 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALOX5 P09917 1/20 0.37
GRK6 P43250 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799213 1.00 CA12 (0.48) CA12ACMSDALPLMCL1CTRC
SCHEMBL21296868 0.90 CA12 (0.46) CA12ACMSDALPLCTRCMIF
SCHEMBL29799100 0.90 CA12 (0.46) CA12ACMSDALPLCTRCMIF
SCHEMBL29799273 0.89 KMT2A (0.43) CA12ALPLMIFHAO1EGLN1
SCHEMBL21296892 0.89 KMT2A (0.43) CA12ALPLMIFHAO1EGLN1
SCHEMBL21296854 0.89 HAO1 (0.44) MCL1PRKAG1PRKAA1PRKAB1HAO1
SCHEMBL22608309 0.86 MCL1 (0.49) MCL1HAO1MEN1KMT2A
SCHEMBL29514714 0.86 MCL1 (0.49) MCL1HAO1MEN1KMT2A
SCHEMBL21296882 0.83 HAO1 (0.44) HAO1KMT2A
SCHEMBL21296859 0.83 HAO1 (0.44) HAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX CA12 843/4885ACMSD 846/4885ALPL 576/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX CA12 843/4885ACMSD 846/4885ALPL 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.